Alkermes (ALKS) Liabilities and Shareholders Equity (2011 - 2026)
Alkermes' (ALKS) quarterly Liabilities and Shareholders Equity came in at $4.3 billion in Q1 2026, up 104.52% year-on-year from $2.1 billion in Q1 2025, and up 71.21% on a QoQ basis from $2.5 billion in Q4 2025.
Alkermes (ALKS) Liabilities and Shareholders Equity (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has 16 years of Liabilities and Shareholders Equity data on file, last reported at $4.3 billion in Q1 2026.
- On a quarterly basis, Liabilities and Shareholders Equity rose 104.52% year-over-year to $4.3 billion in Q1 2026; TTM through Mar 2026 was $11.3 billion, a 33.27% increase from a year earlier, with the FY2025 full-year figure at $2.5 billion, up 20.99% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $4.3 billion, up from $2.5 billion in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for ALKS reached as high as $4.3 billion in Q1 2026 and fell as low as $1.9 billion in Q1 2023.
- Historically, Liabilities and Shareholders Equity has averaged $2.3 billion across 5 years, with a median of $2.1 billion in 2023.
- Across the five-year window, Liabilities and Shareholders Equity slipped 5.44% in 2024 and jumped 104.52% in 2026, its largest moves.
- Year by year, Liabilities and Shareholders Equity stood at $2.0 billion in 2022, then rose by 8.77% to $2.1 billion in 2023, then declined by 3.78% to $2.1 billion in 2024, then climbed by 20.99% to $2.5 billion in 2025, then jumped by 71.21% to $4.3 billion in 2026.
- Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $4.3 billion in Q1 2026, $2.5 billion in Q4 2025, and $2.3 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | 43.40 Bn |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 40.04 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 15.15 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 98.91 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 6.71 Bn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | 25.35 Mn |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 36.83 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 4.91 Bn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 13.22 Bn |
| 10 | Alkermes | 8.78 Bn | 8.26 Bn | 331.33 Mn | 4.26 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.26 Bn |
| Dec 31, 2025 | 2.49 Bn |
| Sep 30, 2025 | 2.33 Bn |
| Jun 30, 2025 | 2.25 Bn |
| Mar 31, 2025 | 2.08 Bn |
| Dec 31, 2024 | 2.06 Bn |
| Sep 30, 2024 | 2.16 Bn |
| Jun 30, 2024 | 2.21 Bn |
| Mar 31, 2024 | 2.12 Bn |
| Dec 31, 2023 | 2.14 Bn |
| Sep 30, 2023 | 2.28 Bn |
| Jun 30, 2023 | 2.19 Bn |
| Mar 31, 2023 | 1.92 Bn |
| Dec 31, 2022 | 1.96 Bn |
| Sep 30, 2022 | 1.94 Bn |
| Jun 30, 2022 | 1.96 Bn |
| Mar 31, 2022 | 1.98 Bn |
| Dec 31, 2021 | 2.02 Bn |
| Sep 30, 2021 | 2.00 Bn |
| Jun 30, 2021 | 1.94 Bn |